SERS Analysis Platform Based on Aptamer Recognition-Release Strategy for Efficient and Sensitive Diagnosis of Colorectal Precancerous Lesions
Fengsong Chen,Yanhua Huang,Yongxia Liu,Yanwen Zhuang,Xiaowei Cao,Xiaogang Qin
DOI: https://doi.org/10.2147/ijn.s483261
IF: 7.033
2024-09-30
International Journal of Nanomedicine
Abstract:Fengsong Chen, 1, &ast Yanhua Huang, 1, &ast Yongxia Liu, 2 Yanwen Zhuang, 3 Xiaowei Cao, 3 Xiaogang Qin 2 1 Department of Gastroenterology, Nantong Haimen People's Hospital, Nantong, Jiangsu, 226100, People's Republic of China; 2 Department of gastroenterology, Traditional Chinese Medicine Hospital of Tongzhou District, Nantong, Jiangsu, 226300, People's Republic of China; 3 Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu, 225001, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaogang Qin, Email Background: Colorectal cancer (CRC) has become a significant global public health challenge, demanding immediate attention due to its high incidence and mortality rates. Regular CRC screening is essential for the early detection of precancerous lesions and CRC. Methods: : We developed a novel surface-enhanced Raman scattering (SERS) analysis platform that employs high-throughput microarray chips as carriers and Au/SnO 2 nanoring arrays (Au/SnO 2 NRAs) as substrates. This platform utilizes an aptamer recognition-release strategy to achieve efficient and sensitive detection of protein tumor markers. In the detection process, the strong affinity and high specificity between the aptamer and the target protein result in competitive replacement of the SERS nanoprobes originally bound to the substrate surface. As a result, the SERS nanoprobes carrying Raman reporter genes are dislodged, leading to a reduction in the SERS signal intensity. Results: The platform demonstrated excellent detection performance, with rapid detection completed within 15 minutes and limits of detection (LOD) as low as 6.2× 10 − 12 g/mL for hnRNP A1 and 6.51× 10 − 12 g/mL for S100P. Clinical samples analyzed using the SERS platform showed high consistency with enzyme-linked immunosorbent assay (ELISA) results. Conclusion: This platform offers strong support for the early detection, risk assessment, and treatment monitoring of colorectal cancer precancerous lesions, with broad potential for clinical applications. Keywords: colorectal cancer, precancerous lesions, surface enhanced raman scattering, aptamer, microarray chip Colorectal cancer (CRC) is one of the most prevalent malignant tumors of the gastrointestinal tract. 1 Due to the lack of distinct early symptoms, CRC is often overlooked by patients, leading to a majority being diagnosed at advanced stages. 2 The high morbidity and mortality rates associated with CRC pose a significant threat to human health and life. 3,4 Detecting and intervening in precancerous lesions at an early stage is crucial for improving the survival rate of CRC patients. 5 Currently, traditional methods, such as colonoscopy, are challenging to implement on a large scale in the general population due to their invasiveness, the complexity of the instrumentation, intricate procedures, and patient intolerance. 6 In recent years, multi-targeted fecal DNA testing has emerged as a non-invasive CRC screening method. It has gained popularity due to its non-invasiveness, painlessness, safety, and convenience. However, it remains hindered by high costs and low specificity. 7,8 Thus, the search for novel CRC biomarkers and diagnostic tools has become a key focus in current research. 9–11 For instance, Lee et al developed a surface plasmon resonance biosensor based on heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1), which was used to analyze plasma samples for CRC. 12 Shen's team identified elevated expression of S100 calcium-binding protein P (S100P) in CRC patient tissues, finding it to be closely associated with CRC invasiveness and metastasis. 13 hnRNP A1 and S100P have both been proposed as potential diagnostic biomarkers for CRC. Several detection methods for protein biomarkers have been extensively reported, including enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), and mass spectrometry analysis. 14–16 However, these methods are often hindered by complex operations and poor accuracy, making them unsuitable for large-scale sample analysis. 17 Surface-enhanced Raman spectroscopy (SERS) is a vibrational fingerprint spectroscopy technique known for its extremely high sensitivity and accuracy. 18 SERS enhances weak Raman signals by utilizing surface nanostructures and surface plasmon resonance effects, allowing for the precise detection of trace compounds. 19 It holds great potential in the detection and analysis of body fluids, d -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology